Compare Stocks: NCNA, AYTU, BFRI, and LPCN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.12 +6.0%	$2.22	$1.65 ▼ $3.07	$22.75M	0.26	21,185 shs	54,647 shs
BFRI Biofrontera	$1.32 +6.5%	$1.31	$0.55 ▼ $1.66	$19.60M	0.83	796,121 shs	375,462 shs
LPCN Lipocine	$2.21 -0.5%	$2.19	$1.81 ▼ $12.37	$18.22M	0.47	28,886 shs	48,486 shs
NCNA NuCana	$1.34 +0.8%	$1.39	$1.21 ▼ $7.22	$5.58M	2.23	88,713 shs	10,972 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	0.00%	+6.53%	-7.02%	-8.23%	-8.62%
BFRI Biofrontera	0.00%	-14.84%	-10.81%	+33.74%	+55.29%
LPCN Lipocine	0.00%	-2.64%	+5.74%	-5.15%	-22.46%
NCNA NuCana	0.00%	+1.52%	-12.42%	-29.84%	-66.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.12 +6.0%	$2.22	$1.65 ▼ $3.07	$22.75M	0.26	21,185 shs	54,647 shs
BFRI Biofrontera	$1.32 +6.5%	$1.31	$0.55 ▼ $1.66	$19.60M	0.83	796,121 shs	375,462 shs
LPCN Lipocine	$2.21 -0.5%	$2.19	$1.81 ▼ $12.37	$18.22M	0.47	28,886 shs	48,486 shs
NCNA NuCana	$1.34 +0.8%	$1.39	$1.21 ▼ $7.22	$5.58M	2.23	88,713 shs	10,972 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	0.00%	+6.53%	-7.02%	-8.23%	-8.62%
BFRI Biofrontera	0.00%	-14.84%	-10.81%	+33.74%	+55.29%
LPCN Lipocine	0.00%	-2.64%	+5.74%	-5.15%	-22.46%
NCNA NuCana	0.00%	+1.52%	-12.42%	-29.84%	-66.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYTU Aytu BioPharma	2.25	Hold	$10.75	407.08% Upside
BFRI Biofrontera	2.00	Hold	N/A	N/A
LPCN Lipocine	1.50	Reduce	$15.00	578.73% Upside
NCNA NuCana	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest NCNA, AYTU, BFRI, and LPCN Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/3/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	LPCN Lipocine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	NCNA NuCana	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	BFRI Biofrontera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/15/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/6/2026	AYTU Aytu BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/29/2026	BFRI Biofrontera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYTU Aytu BioPharma	$66.38M	0.34	$0.38 per share	5.65	$2.11 per share	1.00
BFRI Biofrontera	$41.71M	0.47	N/A	N/A	$0.90 per share	1.47
LPCN Lipocine	$1.98M	9.20	N/A	N/A	$2.61 per share	0.85
NCNA NuCana	N/A	N/A	N/A	N/A	$7.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYTU Aytu BioPharma	-$13.56M	-$4.58	N/A	8.48	N/A	-60.17%	-69.93%	-13.25%	9/29/2026 (Estimated)
BFRI Biofrontera	-$10.54M	-$0.45	N/A	N/A	N/A	-13.78%	-145.81%	-31.30%	11/11/2026 (Estimated)
LPCN Lipocine	-$9.63M	-$1.79	N/A	N/A	N/A	-755.39%	-64.75%	-57.62%	11/5/2026 (Estimated)
NCNA NuCana	-$38.71M	-$3.81	N/A	N/A	N/A	N/A	-41.90%	-33.69%	11/12/2026 (Estimated)

Latest NCNA, AYTU, BFRI, and LPCN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/29/2026	Q4 2026	AYTU Aytu BioPharma	-$0.29	N/A	N/A	N/A	$12.28 million	N/A
8/13/2026	Q2 2026	BFRI Biofrontera	-$0.1050	-$0.05	+$0.0550	-$0.05	$9.50 million	$12.00 million
8/13/2026	Q2 2026	NCNA NuCana	-$2.6514	-$0.99	+$1.6614	N/A	N/A	N/A
8/4/2026	Q2 2026	LPCN Lipocine	-$0.40	-$0.32	+$0.08	-$0.32	$0.21 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYTU Aytu BioPharma	0.27	1.12	1.00
BFRI Biofrontera	0.78	1.18	1.08
LPCN Lipocine	N/A	11.48	11.48
NCNA NuCana	N/A	4.73	4.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYTU Aytu BioPharma	33.49%
BFRI Biofrontera	10.08%
LPCN Lipocine	9.11%
NCNA NuCana	44.00%

Insider Ownership

Company	Insider Ownership
AYTU Aytu BioPharma	4.90%
BFRI Biofrontera	8.10%
LPCN Lipocine	4.69%
NCNA NuCana	31.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYTU Aytu BioPharma	83	10.73 million	10.21 million	Not Optionable
BFRI Biofrontera	94	14.85 million	13.65 million	No Data
LPCN Lipocine	14	8.24 million	7.86 million	No Data
NCNA NuCana	11	4.16 million	2.86 million	Not Optionable

NCNA, AYTU, BFRI, and LPCN Headlines

Recent News About These Companies

NuCana stock gets little fresh support on September 5, 2026

September 5, 2026 | ad-hoc-news.deA

NuCana Files Q2 2026 Results and Updates U.S. Registration Statements

August 16, 2026 | theglobeandmail.com

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | globenewswire.com

NuCana plc Sponsored ADR

June 16, 2026 | edition.cnn.com

NuCana Appoints Ian Webster as Chief Financial Officer

June 1, 2026 | globenewswire.com

NuCana Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026 | globenewswire.com

NuCana Posts 2025 Results, Highlights NUC-7738 Progress and Cash Runway Into 2029

March 22, 2026 | theglobeandmail.com

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

March 19, 2026 | globenewswire.com

NuCana plc: NuCana Appoints Theresa Bruce as Chief Operating Officer

January 6, 2026 | finanznachrichten.de

NuCana appoints Bruce as COO

January 6, 2026 | msn.com

NuCana Appoints Theresa Bruce as Chief Operating Officer

January 6, 2026 | globenewswire.com

NuCana announces return of CEO Hugh S Griffith following health leave

December 17, 2025 | msn.com

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 ...

December 10, 2025 | bakersfield.comB

NuCana presents latest clinical data at ESMO 2025 on NUC-7738

December 10, 2025 | msn.com

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

December 10, 2025 | globenewswire.com

NuCana Reports Q3 2025 Financial Results and Board Resignation

November 13, 2025 | msn.com

NuCana plc: NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

November 13, 2025 | finanznachrichten.de

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

November 13, 2025 | globenewswire.com

NuCana stock rises after securing key patent in China for cancer drug

November 5, 2025 | za.investing.com

NuCana Shares Climb After Securing Key Chinese Patent for Cancer Drug NUC-7738

November 5, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA, AYTU, BFRI, and LPCN Company Descriptions

Aytu BioPharma NASDAQ:AYTU

$2.12 +0.12 (+6.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.12 0.00 (-0.24%)

As of 09/18/2026 07:30 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Biofrontera NASDAQ:BFRI

$1.32 +0.08 (+6.45%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.31 -0.01 (-0.98%)

As of 09/18/2026 07:58 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Lipocine NASDAQ:LPCN

$2.21 -0.01 (-0.45%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.22 +0.00 (+0.23%)

As of 09/18/2026 04:10 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

NuCana NASDAQ:NCNA

$1.34 +0.01 (+0.75%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.33 -0.01 (-0.75%)

As of 09/18/2026 07:30 PM Eastern

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NCNA, AYTU, BFRI, and LPCN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NCNA, AYTU, BFRI, and LPCN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NCNA, AYTU, BFRI, and LPCN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA, AYTU, BFRI, and LPCN Company Descriptions

Aytu BioPharma NASDAQ:AYTU

Biofrontera NASDAQ:BFRI

Lipocine NASDAQ:LPCN

NuCana NASDAQ:NCNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NCNA, AYTU, BFRI, and LPCN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NCNA, AYTU, BFRI, and LPCN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NCNA, AYTU, BFRI, and LPCN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA, AYTU, BFRI, and LPCN Company Descriptions

Aytu BioPharma NASDAQ:AYTU

Biofrontera NASDAQ:BFRI

Lipocine NASDAQ:LPCN

NuCana NASDAQ:NCNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools